Hostname: page-component-8448b6f56d-mp689 Total loading time: 0 Render date: 2024-04-17T05:59:28.173Z Has data issue: false hasContentIssue false
  • English
  • Français

Deconstructing violence as a medical syndrome: mapping psychotic, impulsive, and predatory subtypes to malfunctioning brain circuits

Published online by Cambridge University Press:  09 October 2014

Stephen M. Stahl
Get access Rights & Permissions [Opens in a new window]

Abstract

ISSUE:Violence is a major management issue for forensic mental health systems. Violence can be approached as a medical syndrome and deconstructed into psychotic, impulsive, and predatory subtypes, which are hypothetically mapped onto corresponding malfunctioning brain circuits. Rational management of violence balances treatment with security, while targeting each subtype of violence with approaches unique to the psychotic, impulsive, and predatory forms of violence.

Type
Brainstorms
Information
CNS Spectrums , Volume 19 , Issue 5 , October 2014 , pp. 357 - 365
Copyright
Copyright © Cambridge University Press 2014 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Warburton, K. The new mission of forensic mental health systems: managing violence as a medial syndrome in an environment that balances treatment and safety. CNS Spectr. In press. DOI: 10.1017/S109285291400025X.Google Scholar
2. Stahl, SM, Morrissette, DA, Cummings, M, etal. The California Department of State Hospitals Violence Assessment and Treatment (CAL-VAT) guidelines. CNS Spectr. In press. DOI: 10.1017/S109285291400376.Google Scholar
3. Stahl, SM, Morrissette, DA, Citrome, L, etal. “Meta-guidelines” for the management of patients with schizophrenia. CNS Spectr. 2013; 18(3): 150–162.Google Scholar
4. Correll, CU. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry. 2010; 25(Suppl 2): S12–21.Google Scholar
5. Davis, JM, Chen, N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol. 2004; 24(2): 192–208.Google Scholar
6. Krakowski, MI, Kunz, M, Czobor, P, Volavka, J. Long-term high-dose neuroleptic treatment: who gets it and why? Hosp Community Psychiatry. 1993; 44(7): 640–644.Google Scholar
7. Comai, S, Tau, M, Gobbi, G. The psychopharmacology of aggressive behavior: a translational approach: part 1: neurobiology. J Clin Psychopharmacol. 2012; 32(1): 83–94.CrossRefGoogle ScholarPubMed
8. Comai, S, Tau, M, Pavlovic, Z, Gobbi, G. The psychopharmacology of aggressive behavior: a translational approach: part 2: clinical studies using atypical antipsychotics, anticonvulsants, and lithium. J Clin Psychopharmacol. 2012; 32(2): 237–260.Google Scholar
9. Citrome, L, Volavka, J. The psychopharmacology of violence: making sensible decisions. CNS Spectr. In press. DOI: 10.1017/S109285291400054.Google Scholar
10. Volavka, J, Czobor, P, Citrome, L, Van Dorn, RA. Effectiveness of antipsychotic drugs against hostility with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study. CNS Spectr. In press. DOI: 10.1017/S1092852913000849.Google Scholar
11. Meyer, JM. A rational approach to employing high plasma levels of antipsychotics for violence associated with schizophrenia: case vignettes. CNS Spectr. In press. DOI: 10.1017/S10928514000236.Google Scholar
12. Morrissette, DA, Stahl, SM. Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy. CNS Spectr. In press. DOI: 10.1017/S1092852914000388.Google Scholar
13. Stahl, SM. Emerging guidelines for the use of antipsychotic polypharmacy. Rev Psiquiatr Salud Ment. 2013; 6(3): 97–100.Google Scholar
14. Stahl, SM. Antipsychotic polypharmacy: never say never, but never say always. Acta Psychiatr Scand. 2012; 125(5): 349–351.Google Scholar
15. Morrissette, DA, Stahl, SM. Should high dose or very long-term antipsychotic monotherapy be considered before antipsychotic polypharmacy? In Ritsner MS, ed. Polypharmacy in Psychiatric Practice, Volume 1: Multiple Medication Use Strategies. Heidelberg: Springer; 2013: 107–125.Google Scholar
16. Volavka, J, Citrome, L. Pathways to aggression in schizophrenia affect results of treatment. Schizophr Bull. 2011; 37(5): 921–929.Google Scholar
17. Volavka, J, Citrome, L. Heterogeneity of violence in schizophrenia and implications for long-term treatment. Int J Clin Pract. 2008; 62(8): 1237–1245.Google Scholar
18. Frogley, C, Taylor, D, Dickens, G, Picchioni, M. A systematic review of the evidence of clozapine's anti-aggressive effects. Int J Neuropsychopharmacol. 2012; 15(9): 1351–1371.CrossRefGoogle ScholarPubMed
19. Stilwell, EN, Yates, SE, Brahm, NC. Violence among persons diagnosed with schizophrenia: how pharmacists can help. Res Social Adm Pharm. 2011; 7(4): 421–429.Google Scholar
20. Swanson, JW, Swartz, MS, Van Dorn, RA, etal. Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. Br J Psychiatry. 2008; 193(1): 37–43.Google Scholar
21. Volavka, J, Czobor, P, Nolan, K, etal. Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychopharmacol. 2004; 24(2): 225–228.Google Scholar
22. Topiwala, A, Fazel, S. The pharmacological management of violence in schizophrenia: a structured review. Expert Rev Neurother. 2011; 11(1): 53–63.Google Scholar
23. Bourget, D, Labelle, A. Managing pathologic aggression in people with psychotic disorders. J Psychiatry Neurosci. 2012; 37(2): E3–E4.Google Scholar
24. Citrome, L, Volavka, J. Pharmacological management of acute and persistent aggression in forensic psychiatry settings. CNS Drugs. 2011; 25(12): 1009–1021.Google Scholar
25. Roh, D, Chang, JG, Kim, CH, Cho, HS, An, SK, Jung, YC. Antipsychotic polypharmacy and high-dose prescription in schizophrenia: a 5-year comparison. Aust N Z J Psychiatry. 2014; 48(1): 52–60.Google Scholar
26. Barnes, TR, Paton, C. Antipsychotic polypharmacy in schizophrenia: benefits and risks. CNS Drugs. 2011; 25(5): 383–399.Google Scholar
27. Fleischhacker, WW, Uchida, H. Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. Int J Neuropsychopharmacol. Jul; 17(7): 1083–1093.CrossRefGoogle Scholar
28. Fujita, J, Nishida, A, Sakata, M, Noda, T, Ito, H. Excessive dosing and polypharmacy of antipsychotics caused by pro re nata in agitated patients with schizophrenia. Psychiatry Clin Neurosci. 2013; 67(5): 345–351.Google Scholar
29. Gallego, JA, Bonetti, J, Zhang, J, Kane, JM, Correll, CU. Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res. 2012; 138(1): 18–28.Google Scholar
30. Lochmann van Bennekom, MW, Gijsman, HJ, Zitman, FG. Antipsychotic polypharmacy in psychotic disorders: a critical review of neurobiology, efficacy, tolerability and cost effectiveness. J Psychopharmacol. 2013; 27(4): 327–336.Google Scholar
31. Langle, G, Steinert, T, Weiser, P, etal. Effects of polypharmacy on outcome in patients with schizophrenia in routine psychiatric treatment. Acta Psychiatr Scand. 2012; 125(5): 372–381.CrossRefGoogle ScholarPubMed
32. Essock, SM, Schooler, NR, Stroup, TS, etal. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry. 2011; 168(7): 702–708.Google Scholar
33. Suzuki, T, Uchida, H, Tanaka, KF, etal. Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia. Int J Neuropsychopharmacol. 2004; 7(2): 133–142.CrossRefGoogle ScholarPubMed
34. Stahl, SM, Grady, MM. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Curr Med Chem. 2004; 11(3): 313–327.Google Scholar
35. Aggarwal, NK, Sernyak, MJ, Rosenheck, RA. Prevalence of concomitant oral antipsychotic drug use among patients treated with long-acting, intramuscular, antipsychotic medications. J Clin Psychopharmacol. 2012; 32(3): 323–328.Google Scholar
36. Stahl, SM. The last Diagnostic and Statistical Manual (DSM): replacing our symptom-based diagnoses with a brain circuit-based classification of mental illnesses. CNS Spectr. 2013; 18(2): 65–68.Google Scholar
37. Singh, JP, Serper, M, Reinharth, J, Fazel, S. Structured assessment of violence risk in schizophrenia and other psychiatric disorders: a systematic review of the validity, reliability, and item content of 10 available instruments. Schizophr Bull. 2011; 37(5): 899–912.Google Scholar
38. Nolan, KA, Czobor, P, Roy, BB, etal. Characteristics of assaultive behavior among psychiatric inpatients. Psychiatr Serv. 2003; 54(7): 1012–1016.CrossRefGoogle ScholarPubMed
39. Abderhalden, C, Needham, I, Dassen, T, Halfens, R, Haug, HJ, Fischer, J. Predicting inpatient violence using an extended version of the Brøset-Violence-Checklist: instrument development and clinical application. BMC Psychiatry. 2006; 6: 17.Google Scholar
40. Quanbeck, CD, McDermott, BE, Lam, J, Eisenstark, H, Sokolov, G, Scott, CL. Categorization of aggressive acts committed by chronically assaultive state hospital patients. Psychiatr Serv. 2007; 58(4): 521–528.Google Scholar
41. McDermott, BE, Holoyda, BJ. Assessment of aggression in inpatient settings. CNS Spectr. In press. DOI: 10.1017/S1092852914000224.Google Scholar
42. Monahan, J, Skeem, JL. The evolution of violence risk assessment. CNS Spectr. In press. DOI: 10.1017/S1092852914000145.Google Scholar
43. Stahl, SM, Morrissette, DA. Stahl's Illustrated: Violence: Neural Circuits, Genetics and Treatment. Cambridge, UK: Cambridge University Press; 2014.CrossRefGoogle Scholar
44. Wehring, HJ, Carpenter, WT. Violence and schizophrenia. Schizophr Bull. 2011; 37(5): 877–878.Google Scholar
45. Song, H, Min, SK. Aggressive behavior model in schizophrenic patients. Psychiatry Res. 2009; 167(1–2): 58–65.Google Scholar
46. Serper, M, Beech, DR, Harvey, PD, Dill, C. Neuropsychological and symptom predictors of aggression on the psychiatric inpatient service. J Clin Exp Neuropsychol. 2008; 30(6): 700–709.Google Scholar
47. Stahl, SM. Stahl's Essential Psychopharmacology. 4th ed. New York: Cambridge University Press; 2013.Google Scholar
48. Siever, LJ. Neurobiology of aggression and violence. Am J Psychiatry. 2008; 165(4): 429–442.Google Scholar
49. Nord, M, Farde, L. Antipsychotic occupancy of dopamine receptors in schizophrenia. CNS Neurosci Ther. 2011; 17(2): 97–103.Google Scholar
50. Mauri, MC, Volonteri, LS, Colasanti, A, Fiorentini, A, De Gaspari, IF, Bareggi, SR. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet. 2007; 46(5): 359–388.CrossRefGoogle ScholarPubMed
51. Coccaro, EF, Sripada, CS, Yanowitch, RN, Phan, KL. Corticolimbic function in impulsive aggressive behavior. Biol Psychiatry. 2011; 69(12): 1153–1159.Google Scholar
52. Coccaro, EF, McCloskey, MS, Fitzgerald, DA, Phan, KL. Amygdala and orbitofrontal reactivity to social threat in individuals with impulsive aggression. Biol Psychiatry. 2007; 62(2): 168–178.Google Scholar
53. Hoptman, MJ, Antonius, D. Neuroimaging correlates of aggression in schizophrenia: an update. Curr Opin Psychiatry. 2011; 24(2): 100–106.Google Scholar
54. De Sanctis, P, Foxe, JJ, Czobor, P, etal. Early sensory-perceptual processing deficits for affectively valenced inputs are more pronounced in schizophrenia patients with a history of violence than in their non-violent peers. Soc Cogn Affect Neurosci. 2013; 8(6): 678–687.Google Scholar
55. Kumari, V, Barkataki, I, Goswami, S, Flora, S, Das, M, Taylor, P. Dysfunctional, but not functional, impulsivity is associated with a history of seriously violent behaviour and reduced orbitofrontal and hippocampal volumes in schizophrenia. Psychiatry Res. 2009; 173(1): 39–44.Google Scholar
56. Coccaro, EF. Intermittent explosive disorder as a disorder of impulsive aggression for DSM-5. Am J Psychiatry. 2012; 169(6): 577–588.Google Scholar
57. Haller, J. The neurobiology of abnormal manifestations of aggression—a review of hypothalamic mechanisms in cats, rodents, and humans. Brain Res Bull. 2013; 93: 97–109.Google Scholar
58. Kumari, V, Aasen, I, Taylor, P, etal. Neural dysfunction and violence in schizophrenia: an fMRI investigation. Schizophr Res. 2006; 84(1): 144–164.Google Scholar
59. Krakowski, MI, Czobor, P, Nolan, KA. Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients. J Clin Psychopharmacol. 2008; 28(5): 485–493.Google Scholar
60. Krakowski, MI, Czobor, P. Executive function predicts response to antiaggression treatment in schizophrenia: a randomized controlled trial. J Clin Psychiatry. 2012; 73(1): 74–80.Google Scholar
61. Elie, D, Poirier, M, Chianetta, J, Durand, M, Gregoire, C, Grignon, S. Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder. J Psychopharmacol. 2010; 24(7): 1037–1044.Google Scholar
62. Singh, JP, Volavka, J, Czobor, P, Van Dorn, RA. A meta-analysis of the Val158Met COMT polymorphism and violent behavior in schizophrenia. PloS One. 2012; 7(8): e43423.Google Scholar
63. Pavlov, KA, Chistiakov, DA, Chekhonin, VP. Genetic determinants of aggression and impulsivity in humans. J Appl Genet. 2012; 53(1): 61–82.Google Scholar
64. Rosell, DR, Thompson, JL, Slifstein, M, etal. Increased serotonin 2A receptor availability in the orbitofrontal cortex of physically aggressive personality disordered patients. Biol Psychiatry. 2010; 67(12): 1154–1162.Google Scholar
65. Winstanley, CA, Theobald, DE, Dalley, JW, Glennon, JC, Robbins, TW. 5-HT2A and 5-HT2C receptor antagonists have opposing effects on a measure of impulsivity: interactions with global 5-HT depletion. Psychopharmacology (Berl). 2004; 176(3–4): 376–385.Google Scholar